Inventiva’s stock surged over 80% on news of phase III trial financing for lanifibranor, targeting NASH liver disease. The €94.1 million initial funding will support trials...
Some of the big companies in the biotech sector have already outlined their plans for the new phase. For now, the largest U.S. biotech companies have...
With the $57 million (€50 million), SpliceBio aims to bring this strategy to the clinical phase (human trials) in about 2 to 3 years. Its aim...